Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody persistence and Tdap immunogenicity in 9–12-year-old Thai children
TCTR20240723005Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in diphtheria, Tetanus, pertussis and 4 more, sponsored by Ratchadaphiseksomphot Endowment Fund. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)measles
Beyond the preview
Go deeper on TCTR20240723005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240723005.